New can­cer tar­get? GSK high­lights on­col­o­gy am­bi­tions with its move in­to the clin­ic with RIP1 drug for pan­cre­at­ic can­cer

Re­searchers for Glax­o­SmithK­line are launch­ing a clin­i­cal pro­gram for a RIP1 ki­nase drug in pan­cre­at­ic can­cer af­ter nail­ing down a pos­i­tive look at how this drug worked in mice for pan­cre­at­ic can­cer.

Sci­en­tists at NYU School of Med­i­cine and its Perl­mut­ter Can­cer Cen­ter part­nered with in­ves­ti­ga­tors at GSK on the study, con­clud­ing that the RIP1 ap­proach added to check­point in­hibitors dou­bled the sur­vival time of mice — from 25 days to 50 days.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER